PhotoPill has successfully demonstrated the safety of its digital capsule technology for treating patients with Crohn's disease

REHOVOT, Israel - March 23, 2025 - PRLog -- PhotoPill Medical, a pioneering medical technology company specializing in innovative Photobiomodulation (PBM)-based therapy solutions, today announced the successful completion of the safety phase for its therapeutic electronic capsule, marking a major milestone in the first phase of its groundbreaking First-In-Human (FIH) clinical trial with Crohn's disease patients.

The safety study represents a significant milestone in the clinical development of the company's novel ingestible electronic capsule technology, designed to deliver side-effect free therapy for Crohn's disease. Conducted in accordance with rigorous regulatory standards, the study validates the capsule's safety and tolerability in subjects, paving the way for further clinical investigation into its efficacy in Crohn's Disease patients.

"We are thrilled to accomplish this important milestone in our mission to revolutionize treatment for Crohn's disease," said Sharon Ben Yehuda, founder  & CSO of PhotoPill Medical. "The positive safety results give us confidence as we move forward into the next phase of clinical development."

The First-In-Human study is designed to assess both safety and efficacy of PhotoPill Medical's proprietary capsule-based PBM therapy, which aims to provide precise, targeted treatment while minimizing side effects that are so common in currently available medications. With the successful completion of this safety phase the company is now initiating the efficacy phase, which will further evaluate the therapeutic impact of the capsule on Crohn's disease patients.

Crohn's disease is a chronic inflammatory bowel disease that affects millions of people worldwide, often leading to debilitating, life changing symptoms that significantly impact quality of life. Current treatments are only partially effective and cause both short term ang long term side-effect when using them. PhotoPill Medical's innovative approach seeks to improve patient outcomes by offering a more targeted and side-effect free treatment option.

"We are deeply committed to advance accessible and efficient  solutions that can transform the management of Crohn's disease and other gastrointestinal disorders," added Sharon. "This milestone brings us one step closer to delivering transformative solutions to patients in need".

PhotoPill Medical will continue to collaborate with regulatory agencies, clinical partners, industry players and the broader scientific community as it progresses through the next stages of clinical development. The company remains on track with its timeline and is looking forward to sharing further updates as the study advances.

About PhotoPill Medical

PhotoPill Medical is a leading medical technology company focused on developing cutting-edge solutions for targeted Gastrointestinal non-pharmacological treatments. By leveraging advanced Photobiomodulation based capsule technology, the company aims to improve treatment precision.

www.photopill-med.com